Application of a scoring system in Japanese patients diagnosed with atypical hemolytic uremic syndrome to assess the relationship between the score and clinical responses to eculizumab

Application of a scoring system in Japanese patients diagnosed with atypical hemolytic uremic syndrome to assess the relationship between the score and clinical responses to eculizumab

Abstract Background Atypical hemolytic uremic syndrome (aHUS) is caused by complement dysregulation and is generally diagnosed by exclusion from other disorders of thrombotic microangiopathy (TMA). Eculizumab, a terminal complement inhibitor, has been approved for aHUS treatment since 2013 in Japan....

Full description

Bibliographic Details
Main Authors: Hideo Wada, Hirofumi Teranishi, Akihiko Shimono, Noritoshi Kato, Shoichi Maruyama, Masanori Matsumoto
Format: Article
Language:English
Published: BMC 2023-04-01
Series:Thrombosis Journal
Subjects:
Atypical hemolytic uremic syndrome
Classification
Diagnosis
Eculizumab
Thrombotic microangiopathy
Post-marketing surveillance
Online Access:https://doi.org/10.1186/s12959-023-00489-0

Internet

https://doi.org/10.1186/s12959-023-00489-0

Similar Items